NGD 941
Latest Information Update: 01 Dec 1997
At a glance
- Originator Neurogen Corporation
- Developer Neurogen Corporation; Schering-Plough
- Class Antipsychotics; Imidazoles; Pyrimidines; Small molecules
- Mechanism of Action Dopamine D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 01 Dec 1997 Discontinued-I for Psychotic disorders in USA (Unknown route)
- 22 May 1997 Phase-I clinical trials for Psychotic disorders in USA (Unknown route)
- 07 Feb 1997 No-Development-Reported for Psychotic disorders in USA (Unknown route)